Results 181 to 190 of about 322,744 (314)
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin +11 more
wiley +1 more source
[Spontaneous retrobulbar haemorrhage associated with anticoagulants]. [PDF]
Vicente Altabás MJ +5 more
europepmc +1 more source
ABSTRACT Objective We aim to comprehensively analyze how regional tumor and edema characteristics are associated with clinical presentations and survival outcomes in a large cohort of glioblastoma patients. Methods Patients with IDH‐wildtype glioblastoma who received brain MRI from 2010 to 2023 were included.
Daniel J. Zhou +15 more
wiley +1 more source
[Craniopharyngioma with hemorrhagic presentation and visual impairment in a pregnant woman. Case report and literature review]. [PDF]
Ardila Botero DA, Céspedes Trujillo L.
europepmc +1 more source
[Transnasal endoscopic skull base surgery: analysis of complications in the first 120 procedures]. [PDF]
Rojas HP +5 more
europepmc +1 more source
El presente trabajo abre un nuevo enfoque a la hora de proceder a la evaluación del impacto visual, de aplicabilidad sobre todo en la minería de superficie Aprovechándose del desarrollo de la informática, el autor introduce un método basado en el estudio
Fernández Gutiérrez del Álamo, Luis J.
core +1 more source
MOGAD Is the Most Common Cause of Isolated Optic Neuritis in Children
ABSTRACT Objectives The study aimed to characterize the clinical features, etiologies, and outcomes of isolated, first‐time pediatric ON in the post‐MOG‐IgG era. Methods This was a single‐center retrospective cohort study at Texas Children's Hospital of patients diagnosed with first‐time ON between 2018–2024, with follow‐up data collected through 2025.
Chaitanya Aduru +13 more
wiley +1 more source
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension phase).
Fabrizio De Benedetti +19 more
wiley +1 more source

